Johnson & Johnson (JNJ) Upgraded to Buy by Jefferies Group LLC

Jefferies Group LLC upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a research report sent to investors on Wednesday. Jefferies Group LLC currently has $157.00 target price on the stock, up from their previous target price of $145.00. Jefferies Group also issued estimates for Johnson & Johnson’s FY2017 earnings at $7.22 EPS.

A number of other analysts have also recently weighed in on JNJ. Cowen and Company reiterated an outperform rating and set a $143.00 price target on shares of Johnson & Johnson in a research note on Tuesday, June 13th. Royal Bank Of Canada reiterated a buy rating and set a $128.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 15th. BidaskClub upgraded shares of Johnson & Johnson from a buy rating to a strong-buy rating in a research note on Saturday, June 17th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an overweight rating in a research note on Wednesday, July 5th. Finally, Wells Fargo & Company reiterated a market perform rating and set a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $136.02.

Shares of Johnson & Johnson (JNJ) traded up 0.13% on Wednesday, hitting $136.83. 5,170,003 shares of the company traded hands. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.52. The stock’s 50-day moving average price is $132.32 and its 200-day moving average price is $130.07. The company has a market capitalization of $367.25 billion, a PE ratio of 23.15 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.74 EPS. On average, equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/10/12/johnson-johnson-jnj-upgraded-to-buy-by-jefferies-group-llc.html.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were issued a $0.84 dividend. The ex-dividend date was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.46%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

In other news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Lenox Wealth Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Landmark Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares in the last quarter. Paradigm Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after purchasing an additional 9 shares in the last quarter. Premier Asset Management LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares in the last quarter. Finally, Lbmc Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 1st quarter. Lbmc Investment Advisors LLC now owns 3,704 shares of the company’s stock valued at $461,000 after purchasing an additional 14 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply